Ashland advances high-growth oral biologics delivery applications with launch of permexa™ sodium caprate
Ashland launched permexa™ sodium caprate, an intestinal permeation enhancer designed to support the scalable development of oral peptide and biologic products, including GLP-1 agonists. The product uses an IP-protected process to improve powder flow and compressibility, addressing key manufacturing barriers in oral biologics commercialization.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.